AndrewGreenBull's Blog : A Potential Double in March: GETA

HEPH (symbol changed to HRBR) have had a nice rally since my introduction in December, and it skyrocketed yesterday following the news that the company is going to present results on lead drug candidate Apoptone in ASCO conference this June. I believe that it will continue to move higher and realize my personal target when the milestone is coming near. For more details of HRBR, please find my last post Will HEPH be the Next SNSS? in my blog.

While waiting for the big time to come, I dig into my watch list and search for the next stock that may have a sudden jump in the short-run. Among those stocks which have high possibility to skyrocket, Genta Incorporated (GETA) ranks first.

I wrote several posts about GETA last month and it has been traded in a very narrow range. But I believe that value investors will have a decent return soon, not only because that the current price is a rock bottom, but also because that more catalysts are around the corner.

GETA will attend conferences listed below, and its stock price may be boosted like HRBR, or even better, if it can come out with some good news.

1,3rd Oligonucleotide-based Therapeutics Conference. Tuesday, March 23, 2010 to Thursday, March 25, 2010.

The topic of the presentation is not available yet, but I already contacted GETA’s investor relationships for it. Once I hear anything from them, I will update it here in my Motley Fool blog. It will be a big surprise if they can release some positive clinical data.

2, AACR (American Association for Cancer Research) 101st annual meeting. Saturday, April 17, 2010 to Wednesday, April 21, 2010

This is one of the most important medical conferences in this year. What will GETA present in this conference? Genasense, Tesetaxel, or oral gallium compounds? If GETA comes out with positive news of its lead drug candidate Genasense, we may realize what we are expecting in my topic.

Genasense is GETA’s lead drug candidate for the treatment of advanced melanoma and relapsed or refractory CLL.

3,Rodman & Renshaw Annual 6th Annual Global Healthcare Conference. Sunday, May 16, 2010 to Tuesday, May 18, 2010

As I stated in my previous post, if GETA is willing to sell its Ganite, FDA approved drug for the treatment of hypercalcemia, it surely will find a buyer. But it depends on the terms of the deal. Now here comes the good opportunity to find a satisfactory deal.

The world economy is warming up, so are merger and acquisition activities. If GETA find a merger for Ganite or a collaborative partner for other drug candidates in this conference, we will see another big jump without doubt.

4, American Society of Clinical Oncology (ASCO) Friday, June 04, 2010 to Tuesday, June 08, 2010

News released last month said that GETA initiated a new dose-ranging study of Tesetaxel, and the results will be presented in the annual meeting of ASCO this June.

Tesetaxel is currently in the phase 2 clinical trial, and has been granted the orphan drug designation by FDA for treatment of patients with advanced gastric cancer and for patients with advanced melanoma.

HRBR also will present its phase 2 data of Apoptone in ASCO conference and it had a 30% gain yesterday. The same thing may happen on GETA at anytime if investors are aware of the real value of Tesetaxel. For my opinion, Tesetaxel alone is worth of the whole market capital of GETA.

So will GETA be the next 2 baggers in Mach? Time will tell.

*Disclaimer: The author of this post is not a licensed analyst and the purpose of it is for information sharing and discussion only, not recommendation for any stock buying and selling activity. Please do your own decent research before making any trading decision.